You searched for Cybin - Page 16 of 60

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Likely to Benefit from New Research Touting Psilocybin Mental Health Treatments

Yale researchers publish study that a single dose of psilocybin counteracts symptoms of depression Administering drug to mice resulted in an approximately 10% increase in neuron size and density Cybin is focused on progressing psychedelic therapeutics As news of psychedelic research continues to report breakthroughs — such as the recent news from a group of Yale researchers … Continue reading “Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Likely to Benefit from New Research Touting Psilocybin Mental Health Treatments”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Present Virtually at H.C. Wainwright 23rd Annual Global Investment Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company focused on advancing psychedelic pharmaceutical therapeutics for various psychiatric and neurological conditions, today announced that on Monday, September 13, 2021, Chief Executive Officer Doug Drysdale will be presenting virtually at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be webcast on-demand beginning … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Present Virtually at H.C. Wainwright 23rd Annual Global Investment Conference”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Featured in Article as Stock That Is ‘Shaping up to Be a Brilliant Investment’

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company focused on advancing psychedelic pharmaceutical therapeutics for various psychiatric and neurological conditions, was highlighted in a Motley Fool article titled, “Buying Cybin Stock Right Now Could Be a Brilliant Move.” The piece, written by Alex Carchidi, delves into CYBN as one of those investment opportunities … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Featured in Article as Stock That Is ‘Shaping up to Be a Brilliant Investment’”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports on Milestone Achievements Reached by Subsidiary

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on psychedelic pharmaceutical therapies, has announced that Adelia Therapeutics Inc., its wholly controlled subsidiary, has reached key milestones for Year 1 Q3. The milestones were outlined in last year’s transaction agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and previous shareholders of Adelia. Based on … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports on Milestone Achievements Reached by Subsidiary”

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Applications to Support Research Phase Programs, Strengthen IP Portfolio

Company’s nonprovisional patent application includes claims to compositions, methods to support certain elements of preclinical and research programs Two international patent applications will grant Cybin the right to file future national applications into treaty member jurisdictions Cybin portfolio consists of 14 patent filings, 50-plus proprietary molecules, 50-plus preclinical studies and 4 active drug programs Cybin … Continue reading “Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Applications to Support Research Phase Programs, Strengthen IP Portfolio”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Eyes Fueled Mission to Develop Revolutionary Psychedelic Therapeutics

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, in a recent historic move became the first psychedelic biotech company to trade on the NYSE American LLC stock exchange. “We are all delighted to receive this approval from the NYSE American and are thankful to … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Eyes Fueled Mission to Develop Revolutionary Psychedelic Therapeutics”

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q1 2021 Operational, Financial Report

Q1 2021 report notes distinction of becoming first psychedelic company to list on the NYSE American LLC stock exchange Cybin has garnered “a great deal of attention as an emerging leader in the psychedelic therapeutics space,” says CEO Several of the quarter’s highlights tied into the company’s active development of its psychedelic pipeline Cybin (NEO: CYBN) … Continue reading “Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Q1 2021 Operational, Financial Report”

Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Adelia Acquisition Making Impact, Reaching Milestones

Cybin subsidiary achieved certain milestones as outlined in acquisition agreement Adelia brought numerous advantages to company Acquisition may advance “Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder,” says CEO Cybin’s (NEO: CYBN) (NYSE American CYBN) most recent acquisition, Adelia Therapeutics Inc., is already reporting success for the company … Continue reading “Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Adelia Acquisition Making Impact, Reaching Milestones”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Files Two International Patent Applications in Support of the Company’s Research Phase Programs

Cybin (NEO: CYBN) (NYSE American CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has filed two additional international patent applications; these applications open the possibility for CYBN to obtain patent coverage in 153 countries and, if approved, allow the company to file future national applications into treaty member jurisdictions. The company filed the applications under … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Files Two International Patent Applications in Support of the Company’s Research Phase Programs”

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Files 14th Patent Application, Announces New Board Member

Cybin (NEO: CYBN) (NYSE American CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has filed a nonprovisional patent application in support of its ongoing drug candidate programs. The company noted that it had completed a favorable international search report regarding its May 2021 Patent Cooperation Treaty (“PCT”) application; as a result, it filed the U.S. … Continue reading “QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American CYBN) Files 14th Patent Application, Announces New Board Member”

Site Search

Company Search

Search Results for: Cybin